Nasal Polyps and Aspirin Sensitivity: Understanding AERD

Recognize the three parts of AERD

AERD is defined by asthma, chronic rhinosinusitis with nasal polyps, and respiratory reactions to aspirin or other cyclooxygenase-1-inhibiting nonsteroidal anti-inflammatory drugs. Reactions can include sudden nasal congestion, drainage, eye symptoms, cough, wheeze, chest tightness, or a severe asthma flare. Skin flushing or gastrointestinal symptoms can occur, but isolated stomach upset after an NSAID does not establish AERD.

The disease is acquired rather than present from birth, and the sinus, polyp, asthma, and medicine-reaction history may unfold over several years. Ask about loss of smell, repeated sinus surgery, rapid polyp regrowth, adult-onset asthma, and reactions to more than one NSAID. AERD is not simply a positive allergy test to aspirin and does not require a person to have environmental allergy.

Related care: Respiratory conditions. Compare asthma, chronic sinus disease, and nasal polyp care pathways.

Reconstruct the medicine reaction precisely

Write down the exact medicine, dose when known, reason it was taken, time to symptoms, upper- and lower-airway symptoms, skin or stomach symptoms, treatment, and whether emergency care was needed. Include aspirin, ibuprofen, naproxen, and combination cold, pain, or menstrual products. A reaction to one medicine may be ambiguous; repeated similar respiratory reactions in a person with asthma and polyps carry more diagnostic weight.

Other NSAID hypersensitivity patterns can produce hives or anaphylaxis without the full AERD picture, and ordinary side effects can be mislabeled as allergy. The clinician should separate these phenotypes because the advice about avoidance, challenge, and alternatives differs. Bring old operative reports, sinus imaging, asthma testing, and pharmacy records when possible rather than relying on a vague “allergic to all painkillers” label.

Related care: Nasal polyps. Review evaluation and treatment of chronic rhinosinusitis with nasal polyps.

Do not use a home aspirin trial to confirm the diagnosis

There is no routine skin-prick or blood test that confirms AERD. A compelling history may be sufficient, while an ambiguous history can lead to a physician-observed aspirin challenge. The procedure uses graded exposure with respiratory monitoring in a setting prepared to treat bronchospasm and other reactions. Asthma and sinus disease should be medically optimized first, and some patients are not appropriate candidates.

A diagnostic challenge and aspirin desensitization are related but different decisions. The challenge asks whether the reaction pattern is present; desensitization intentionally establishes temporary tolerance followed by a prescribed maintenance regimen for selected patients. Neither should be attempted with over-the-counter tablets at home, and missing maintenance doses after desensitization requires instructions from the treating team.

Related care: Asthma. Understand objective testing, control assessment, and action planning.

Treat the upper and lower airway as one disease system

Care usually combines guideline-based asthma treatment with management of chronic rhinosinusitis and nasal polyps. Depending on severity, the plan may include inhaled and intranasal corticosteroids, saline irrigation, leukotriene-modifying medicine, sinus surgery, or biologic therapy. Surgery can remove obstructing polyps and improve access for topical treatment, but it does not remove the underlying inflammatory tendency.

The allergist, otolaryngologist, and primary or pulmonary team should share the medication and surgery timeline. Track smell, congestion, infections, oral corticosteroid courses, asthma attacks, reliever use, and polyp recurrence. A plan that improves the nose while asthma remains unstable, or controls asthma while polyps rapidly return, needs coordinated reassessment rather than isolated escalation by one specialty.

Discuss desensitization and biologics as individualized options

Aspirin desensitization followed by maintenance therapy may improve symptoms and delay polyp regrowth for selected patients, but it also creates bleeding, gastrointestinal, adherence, and perioperative considerations. Candidacy depends on the disease burden, other medical conditions, need for aspirin, prior surgery, asthma stability, and ability to maintain the prescribed schedule. Benefits and risks should be reviewed before scheduling the procedure.

Biologic medicines that target type 2 inflammation may be considered for selected asthma or chronic rhinosinusitis with nasal polyps. There is no single best sequence for every patient, and head-to-head evidence for AERD-specific choices is limited. Ask which outcome is being targeted, what prior authorization requires, how response will be measured, and what happens to the rest of the airway plan if the new treatment works only partially.

Create a medication-safety and emergency plan

Until a specialist clarifies the phenotype, avoid the suspected aspirin and cross-reacting NSAIDs and check active ingredients in combination products. Do not assume acetaminophen or a selective COX-2 medicine is safe at every dose for every person; alternatives should be documented by the treating clinician. If aspirin was prescribed for heart or stroke prevention, contact the prescriber promptly rather than stopping it without a coordinated plan.

Call emergency services for severe breathlessness, inability to speak normally, throat or tongue swelling, faintness, confusion, bluish or gray lips, or a rapidly worsening reaction. Follow the asthma and emergency action plans and use prescribed rescue treatment as directed. After any suspected NSAID reaction, record the product and timing and arrange review before trying another pain medicine. A clear written list is safer than relying on memory at a pharmacy or emergency visit.